ID   PINK1_HUMAN             Reviewed;         581 AA.
AC   Q9BXM7; Q8N6T9; Q8NBU3; Q96DE4;
DT   07-JUN-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2001, sequence version 1.
DT   06-JUL-2016, entry version 151.
DE   RecName: Full=Serine/threonine-protein kinase PINK1, mitochondrial;
DE            EC=2.7.11.1 {ECO:0000269|PubMed:24660806, ECO:0000269|PubMed:24751536, ECO:0000269|PubMed:24784582};
DE   AltName: Full=BRPK;
DE   AltName: Full=PTEN-induced putative kinase protein 1;
DE   Flags: Precursor;
GN   Name=PINK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000312|EMBL:AAK28062.1};
RN   [1] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Endometrium {ECO:0000269|PubMed:11494141};
RX   PubMed=11494141; DOI=10.1038/sj.onc.1204608;
RA   Unoki M., Nakamura Y.;
RT   "Growth-suppressive effects of BPOZ and EGR2, two genes involved in
RT   the PTEN signaling pathway.";
RL   Oncogene 20:4457-4465(2001).
RN   [2] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND
RP   AUTOPHOSPHORYLATION.
RC   TISSUE=Placenta {ECO:0000312|EMBL:AAK28062.1};
RX   PubMed=14607334; DOI=10.1016/S0304-3835(03)00443-9;
RA   Nakajima A., Kataoka K., Hong M., Sakaguchi M., Huh N.-H.;
RT   "BRPK, a novel protein kinase showing increased expression in mouse
RT   cancer cell lines with higher metastatic potential.";
RL   Cancer Lett. 201:195-201(2003).
RN   [3] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANTS
RP   THR-340 AND THR-521.
RC   TISSUE=Placenta {ECO:0000312|EMBL:BAC11484.1};
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Leukocyte {ECO:0000312|EMBL:AAH28215.1}, and
RC   Lung {ECO:0000312|EMBL:AAH09534.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   SUBCELLULAR LOCATION, AND MEMBRANE TOPOLOGY.
RX   PubMed=18687899; DOI=10.1073/pnas.0802814105;
RA   Zhou C., Huang Y., Shao Y., May J., Prou D., Perier C., Dauer W.,
RA   Schon E.A., Przedborski S.;
RT   "The kinase domain of mitochondrial PINK1 faces the cytoplasm.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:12022-12027(2008).
RN   [7]
RP   FUNCTION, COMPONENT OF A COMPLEX COMPOSED OF PARK2; PARK7 AND PINK1,
RP   SUBCELLULAR LOCATION, PROTEOLYTIC CLEAVAGE, AND CHARACTERIZATION OF
RP   VARIANTS PARK6 ASP-309; MET-313 AND LEU-399.
RX   PubMed=19229105; DOI=10.1172/JCI37617;
RA   Xiong H., Wang D., Chen L., Choo Y.S., Ma H., Tang C., Xia K.,
RA   Jiang W., Ronai Z., Zhuang X., Zhang Z.;
RT   "Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting
RT   unfolded protein degradation.";
RL   J. Clin. Invest. 119:650-660(2009).
RN   [8]
RP   FUNCTION IN MITOCHONDRIAL AUTOPHAGY, SUBCELLULAR LOCATION, INTERACTION
RP   WITH PARK2, AND CHARACTERIZATION OF VARIANTS PARK6 PRO-126; ASP-309
RP   AND PRO-347.
RX   PubMed=20798600; DOI=10.4161/auto.6.7.13286;
RA   Geisler S., Holmstrom K.M., Treis A., Skujat D., Weber S.S.,
RA   Fiesel F.C., Kahle P.J., Springer W.;
RT   "The PINK1/Parkin-mediated mitophagy is compromised by PD-associated
RT   mutations.";
RL   Autophagy 6:871-878(2010).
RN   [9]
RP   FUNCTION IN MITOCHONDRIAL AUTOPHAGY.
RX   PubMed=20404107; DOI=10.1083/jcb.200910140;
RA   Matsuda N., Sato S., Shiba K., Okatsu K., Saisho K., Gautier C.A.,
RA   Sou Y.S., Saiki S., Kawajiri S., Sato F., Kimura M., Komatsu M.,
RA   Hattori N., Tanaka K.;
RT   "PINK1 stabilized by mitochondrial depolarization recruits Parkin to
RT   damaged mitochondria and activates latent Parkin for mitophagy.";
RL   J. Cell Biol. 189:211-221(2010).
RN   [10]
RP   FUNCTION IN MITOCHONDRIAL AUTOPHAGY, AND INTERACTION WITH PARK2.
RX   PubMed=19966284; DOI=10.1073/pnas.0911187107;
RA   Vives-Bauza C., Zhou C., Huang Y., Cui M., de Vries R.L., Kim J.,
RA   May J., Tocilescu M.A., Liu W., Ko H.S., Magrane J., Moore D.J.,
RA   Dawson V.L., Grailhe R., Dawson T.M., Li C., Tieu K., Przedborski S.;
RT   "PINK1-dependent recruitment of Parkin to mitochondria in mitophagy.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:378-383(2010).
RN   [11]
RP   PHOSPHORYLATION AT SER-228 AND SER-402.
RX   PubMed=22910362; DOI=10.1038/ncomms2016;
RA   Okatsu K., Oka T., Iguchi M., Imamura K., Kosako H., Tani N.,
RA   Kimura M., Go E., Koyano F., Funayama M., Shiba-Fukushima K., Sato S.,
RA   Shimizu H., Fukunaga Y., Taniguchi H., Komatsu M., Hattori N.,
RA   Mihara K., Tanaka K., Matsuda N.;
RT   "PINK1 autophosphorylation upon membrane potential dissipation is
RT   essential for Parkin recruitment to damaged mitochondria.";
RL   Nat. Commun. 3:1016-1016(2012).
RN   [12]
RP   FUNCTION.
RX   PubMed=23754282; DOI=10.1074/jbc.M113.467530;
RA   Iguchi M., Kujuro Y., Okatsu K., Koyano F., Kosako H., Kimura M.,
RA   Suzuki N., Uchiyama S., Tanaka K., Matsuda N.;
RT   "Parkin-catalyzed ubiquitin-ester transfer is triggered by PINK1-
RT   dependent phosphorylation.";
RL   J. Biol. Chem. 288:22019-22032(2013).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH FBXO7.
RX   PubMed=23933751; DOI=10.1038/nn.3489;
RA   Burchell V.S., Nelson D.E., Sanchez-Martinez A., Delgado-Camprubi M.,
RA   Ivatt R.M., Pogson J.H., Randle S.J., Wray S., Lewis P.A., Houlden H.,
RA   Abramov A.Y., Hardy J., Wood N.W., Whitworth A.J., Laman H.,
RA   Plun-Favreau H.;
RT   "The Parkinson's disease-linked proteins Fbxo7 and Parkin interact to
RT   mediate mitophagy.";
RL   Nat. Neurosci. 16:1257-1265(2013).
RN   [14]
RP   FUNCTION IN MITOPHAGY, AND MUTAGENESIS OF LYS-219; ASP-362 AND
RP   ASP-384.
RX   PubMed=23620051; DOI=10.1126/science.1231031;
RA   Chen Y., Dorn G.W. II;
RT   "PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling
RT   damaged mitochondria.";
RL   Science 340:471-475(2013).
RN   [15]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=24660806; DOI=10.1042/BJ20140334;
RA   Kazlauskaite A., Kondapalli C., Gourlay R., Campbell D.G.,
RA   Ritorto M.S., Hofmann K., Alessi D.R., Knebel A., Trost M.,
RA   Muqit M.M.;
RT   "Parkin is activated by PINK1-dependent phosphorylation of ubiquitin
RT   at Ser65.";
RL   Biochem. J. 460:127-139(2014).
RN   [16]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=24751536; DOI=10.1083/jcb.201402104;
RA   Kane L.A., Lazarou M., Fogel A.I., Li Y., Yamano K., Sarraf S.A.,
RA   Banerjee S., Youle R.J.;
RT   "PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase
RT   activity.";
RL   J. Cell Biol. 205:143-153(2014).
RN   [17]
RP   FUNCTION, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANTS PARK6
RP   PRO-168 AND ALA-386.
RX   PubMed=24784582; DOI=10.1038/nature13392;
RA   Koyano F., Okatsu K., Kosako H., Tamura Y., Go E., Kimura M.,
RA   Kimura Y., Tsuchiya H., Yoshihara H., Hirokawa T., Endo T., Fon E.A.,
RA   Trempe J.F., Saeki Y., Tanaka K., Matsuda N.;
RT   "Ubiquitin is phosphorylated by PINK1 to activate parkin.";
RL   Nature 510:162-166(2014).
RN   [18]
RP   FUNCTION.
RX   PubMed=24896179; DOI=10.1038/nature13418;
RA   Bingol B., Tea J.S., Phu L., Reichelt M., Bakalarski C.E., Song Q.,
RA   Foreman O., Kirkpatrick D.S., Sheng M.;
RT   "The mitochondrial deubiquitinase USP30 opposes parkin-mediated
RT   mitophagy.";
RL   Nature 510:370-375(2014).
RN   [19]
RP   FUNCTION.
RX   PubMed=25527291; DOI=10.15252/embj.201489847;
RA   Wauer T., Swatek K.N., Wagstaff J.L., Gladkova C., Pruneda J.N.,
RA   Michel M.A., Gersch M., Johnson C.M., Freund S.M., Komander D.;
RT   "Ubiquitin Ser65 phosphorylation affects ubiquitin structure, chain
RT   assembly and hydrolysis.";
RL   EMBO J. 34:307-325(2015).
RN   [20]
RP   VARIANTS PARK6 PHE-92; PRO-168 AND HIS-464, AND VARIANTS LEU-296;
RP   THR-340; THR-442; LYS-476; THR-521 AND ASN-525.
RX   PubMed=15349860; DOI=10.1002/ana.20256;
RA   Valente E.M., Salvi S., Ialongo T., Marongiu R., Elia A.E., Caputo V.,
RA   Romito L., Albanese A., Dallapiccola B., Bentivoglio A.R.;
RT   "PINK1 mutations are associated with sporadic early-onset
RT   parkinsonism.";
RL   Ann. Neurol. 56:336-341(2004).
RN   [21]
RP   VARIANTS PARK6 GLN-271; PRO-347 AND GLY-417.
RX   PubMed=15349870; DOI=10.1002/ana.20251;
RA   Hatano Y., Li Y., Sato K., Asakawa S., Yamamura Y., Tomiyama H.,
RA   Yoshino H., Asahina M., Kobayashi S., Hassin-Baer S., Lu C.-S.,
RA   Ng A.R., Rosales R.L., Shimizu N., Toda T., Mizuno Y., Hattori N.;
RT   "Novel PINK1 mutations in early-onset parkinsonism.";
RL   Ann. Neurol. 56:424-427(2004).
RN   [22]
RP   ERRATUM.
RA   Hatano Y., Li Y., Sato K., Asakawa S., Yamamura Y., Tomiyama H.,
RA   Yoshino H., Asahina M., Kobayashi S., Hassin-Baer S., Lu C.-S.,
RA   Ng A.R., Rosales R.L., Shimizu N., Toda T., Mizuno Y., Hattori N.;
RL   Ann. Neurol. 56:603-603(2004).
RN   [23]
RP   VARIANTS PARK6 LYS-240; PRO-347 AND PRO-489, AND VARIANTS GLY-231;
RP   ILE-235; GLY-263; LEU-318; THR-339; THR-340; HIS-362; SER-425; LYS-476
RP   AND THR-521.
RX   PubMed=15596610; DOI=10.1001/archneur.61.12.1898;
RA   Rogaeva E., Johnson J., Lang A.E., Gulick C., Gwinn-Hardy K.,
RA   Kawarai T., Sato C., Morgan A., Werner J., Nussbaum R., Petit A.,
RA   Okun M.S., McInerney A., Mandel R., Groen J.L., Fernandez H.H.,
RA   Postuma R., Foote K.D., Salehi-Rad S., Liang Y., Reimsnider S.,
RA   Tandon A., Hardy J., St George-Hyslop P., Singleton A.B.;
RT   "Analysis of the PINK1 gene in a large cohort of cases with Parkinson
RT   disease.";
RL   Arch. Neurol. 61:1898-1904(2004).
RN   [24]
RP   VARIANT PARK6 HIS-147.
RX   PubMed=15505171; DOI=10.1212/01.WNL.0000142089.38301.8E;
RA   Healy D.G., Abou-Sleiman P.M., Gibson J.M., Ross O.A., Jain S.,
RA   Gandhi S., Gosal D., Muqit M.M.K., Wood N.W., Lynch T.;
RT   "PINK1 (PARK6) associated Parkinson disease in Ireland.";
RL   Neurology 63:1486-1488(2004).
RN   [25]
RP   VARIANT PARK6 ASP-309, CHARACTERIZATION OF VARIANT PARK6 ASP-309,
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15087508; DOI=10.1126/science.1096284;
RA   Valente E.M., Abou-Sleiman P.M., Caputo V., Muqit M.M.K., Harvey K.,
RA   Gispert S., Ali Z., Del Turco D., Bentivoglio A.R., Healy D.G.,
RA   Albanese A., Nussbaum R., Gonzalez-Maldonado R., Deller T., Salvi S.,
RA   Cortelli P., Gilks W.P., Latchman D.S., Harvey R.J., Dallapiccola B.,
RA   Auburger G., Wood N.W.;
RT   "Hereditary early-onset Parkinson's disease caused by mutations in
RT   PINK1.";
RL   Science 304:1158-1160(2004).
RN   [26]
RP   VARIANT PARK6 VAL-268.
RX   PubMed=16207217; DOI=10.1111/j.1399-0004.2005.00500.x;
RA   Tan E.K., Yew K., Chua E., Shen H., Jamora R.D., Lee E., Puong K.Y.,
RA   Zhao Y., Pavanni R., Wong M.C., Puvan K., Yih Y., Tan L.C.S.;
RT   "Analysis of PINK1 in Asian patients with familial parkinsonism.";
RL   Clin. Genet. 68:468-470(2005).
RN   [27]
RP   VARIANTS PARK6 HIS-279 AND GLN-534 INS, AND VARIANT LEU-115.
RX   PubMed=15970950; DOI=10.1038/sj.ejhg.5201455;
RA   Klein C., Djarmati A., Hedrich K., Schaefer N., Scaglione C.,
RA   Marchese R., Kock N., Schuele B., Hiller A., Lohnau T., Winkler S.,
RA   Wiegers K., Hering R., Bauer P., Riess O., Abbruzzese G.,
RA   Martinelli P., Pramstaller P.P.;
RT   "PINK1, Parkin, and DJ-1 mutations in Italian patients with early-
RT   onset parkinsonism.";
RL   Eur. J. Hum. Genet. 13:1086-1093(2005).
RN   [28]
RP   CHARACTERIZATION OF VARIANTS PARK6 PRO-168 AND ASP-309.
RX   PubMed=16207731; DOI=10.1093/hmg/ddi377;
RA   Silvestri L., Caputo V., Bellacchio E., Atorino L., Dallapiccola B.,
RA   Valente E.M., Casari G.;
RT   "Mitochondrial import and enzymatic activity of PINK1 mutants
RT   associated to recessive parkinsonism.";
RL   Hum. Mol. Genet. 14:3477-3492(2005).
RN   [29]
RP   VARIANT PARK6 ARG-388.
RX   PubMed=15955953; DOI=10.1212/01.WNL.0000164009.36740.4E;
RA   Li Y., Tomiyama H., Sato K., Hatano Y., Yoshino H., Atsumi M.,
RA   Kitaguchi M., Sasaki S., Kawaguchi S., Miyajima H., Toda T.,
RA   Mizuno Y., Hattori N.;
RT   "Clinicogenetic study of PINK1 mutations in autosomal recessive early-
RT   onset parkinsonism.";
RL   Neurology 64:1955-1957(2005).
RN   [30]
RP   VARIANTS PARK6 PRO-168 AND LEU-196, AND VARIANTS LEU-115; THR-340;
RP   LYS-476 AND THR-521.
RX   PubMed=16009891; DOI=10.1212/01.wnl.0000167546.39375.82;
RG   The Italian Parkinson genetics network;
RA   Bonifati V., Rohe C.F., Breedveld G.J., Fabrizio E., De Mari M.,
RA   Tassorelli C., Tavella A., Marconi R., Nicholl D.J., Chien H.F.,
RA   Fincati E., Abbruzzese G., Marini P., De Gaetano A., Horstink M.W.,
RA   Maat-Kievit J.A., Sampaio C., Antonini A., Stocchi F., Montagna P.,
RA   Toni V., Guidi M., Dalla Libera A., Tinazzi M., De Pandis F.,
RA   Fabbrini G., Goldwurm S., de Klein A., Barbosa E., Lopiano L.,
RA   Martignoni E., Lamberti P., Vanacore N., Meco G., Oostra B.A.;
RT   "Early-onset parkinsonism associated with PINK1 mutations: frequency,
RT   genotypes, and phenotypes.";
RL   Neurology 65:87-95(2005).
RN   [31]
RP   VARIANTS ILE-317; THR-339; THR-383; SER-411; HIS-431; SER-451;
RP   SER-461; LYS-476; PRO-501 AND ARG-575, AND CHARACTERIZATION OF
RP   VARIANTS HIS-431; SER-451; LYS-476; PRO-501 AND ARG-575.
RX   PubMed=16969854; DOI=10.1002/ana.20960;
RA   Abou-Sleiman P.M., Muqit M.M.K., McDonald N.Q., Yang Y.X., Gandhi S.,
RA   Healy D.G., Harvey K., Harvey R.J., Deas E., Bhatia K., Quinn N.,
RA   Lees A., Latchman D.S., Wood N.W.;
RT   "A heterozygous effect for PINK1 mutations in Parkinson's disease?";
RL   Ann. Neurol. 60:414-419(2006).
RN   [32]
RP   VARIANT PARK6 ASP-217.
RX   PubMed=16966503; DOI=10.1001/archneur.63.9.1257;
RA   Leutenegger A.-L., Salih M.A.M., Ibanez P., Mukhtar M.M., Lesage S.,
RA   Arabi A., Lohmann E., Duerr A., Ahmed A.E.M., Brice A.;
RT   "Juvenile-onset Parkinsonism as a result of the first mutation in the
RT   adenosine triphosphate orientation domain of PINK1.";
RL   Arch. Neurol. 63:1257-1261(2006).
RN   [33]
RP   VARIANT PARK6 MET-313.
RX   PubMed=17030667; DOI=10.1001/archneur.63.10.1483;
RA   Chishti M.A., Bohlega S., Ahmed M., Loualich A., Carroll P., Sato C.,
RA   St George-Hyslop P., Westaway D., Rogaeva E.;
RT   "T313M PINK1 mutation in an extended highly consanguineous Saudi
RT   family with early-onset Parkinson disease.";
RL   Arch. Neurol. 63:1483-1485(2006).
RN   [34]
RP   VARIANTS PARK6 GLY-125; LYS-240; PRO-369; ALA-386 AND VAL-409.
RX   PubMed=16401616; DOI=10.1093/brain/awl005;
RG   The French Parkinson's disease genetics study group;
RA   Ibanez P., Lesage S., Lohmann E., Thobois S., De Michele G., Borg M.,
RA   Agid Y., Durr A., Brice A.;
RT   "Mutational analysis of the PINK1 gene in early-onset parkinsonism in
RT   Europe and North Africa.";
RL   Brain 129:686-694(2006).
RN   [35]
RP   VARIANT LEU-399.
RX   PubMed=16632486; DOI=10.1093/hmg/ddl104;
RA   Tang B., Xiong H., Sun P., Zhang Y., Wang D., Hu Z., Zhu Z., Ma H.,
RA   Pan Q., Xia J.-H., Xia K., Zhang Z.;
RT   "Association of PINK1 and DJ-1 confers digenic inheritance of early-
RT   onset Parkinson's disease.";
RL   Hum. Mol. Genet. 15:1816-1825(2006).
RN   [36]
RP   VARIANT PARK6 THR-280, AND VARIANTS THR-340 AND THR-521.
RX   PubMed=16482571; DOI=10.1002/mds.20810;
RA   Tan E.-K., Yew K., Chua E., Puvan K., Shen H., Lee E., Puong K.-Y.,
RA   Zhao Y., Pavanni R., Wong M.-C., Jamora D., de Silva D., Moe K.-T.,
RA   Woon F.-P., Yuen Y., Tan L.;
RT   "PINK1 mutations in sporadic early-onset Parkinson's disease.";
RL   Mov. Disord. 21:789-793(2006).
RN   [37]
RP   VARIANT PARK6 GLN-407, AND VARIANTS THR-340 AND THR-521.
RX   PubMed=16257123; DOI=10.1016/j.neulet.2005.10.005;
RA   Fung H.-C., Chen C.-M., Hardy J., Singleton A.B., Lee-Chen G.-J.,
RA   Wu Y.-R.;
RT   "Analysis of the PINK1 gene in a cohort of patients with sporadic
RT   early-onset parkinsonism in Taiwan.";
RL   Neurosci. Lett. 394:33-36(2006).
RN   [38]
RP   VARIANTS [LARGE SCALE ANALYSIS] TRP-148; SER-196; LEU-209; LEU-215;
RP   THR-339; THR-340; ILE-341; PHE-377; THR-477 AND THR-521.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [39]
RP   VARIANTS PHE-67; PRO-68; TRP-98; SER-111; VAL-124; MET-145; ASN-186;
RP   ILE-257 VAL-268; GLN-276; LEU-296; ILE-317; LEU-322; THR-339; THR-383;
RP   VAL-395; THR-442; LYS-476; ASN-525 AND THR-537.
RX   PubMed=18330912; DOI=10.1002/humu.20719;
RG   The Italian PD study group;
RA   Marongiu R., Ferraris A., Ialongo T., Michiorri S., Soleti F.,
RA   Ferrari F., Elia A.E., Ghezzi D., Albanese A., Altavista M.C.,
RA   Antonini A., Barone P., Brusa L., Cortelli P., Martinelli P.,
RA   Pellecchia M.T., Pezzoli G., Scaglione C., Stanzione P., Tinazzi M.,
RA   Zecchinelli A., Zeviani M., Cassetta E., Garavaglia B.,
RA   Dallapiccola B., Bentivoglio A.R., Valente E.M.;
RT   "PINK1 heterozygous rare variants: prevalence, significance and
RT   phenotypic spectrum.";
RL   Hum. Mutat. 29:565-565(2008).
RN   [40]
RP   VARIANT PARK6 PRO-126.
RX   PubMed=18286320; DOI=10.1007/s00415-008-0763-4;
RA   Prestel J., Gempel K., Hauser T.K., Schweitzer K., Prokisch H.,
RA   Ahting U., Freudenstein D., Bueltmann E., Naegele T., Berg D.,
RA   Klopstock T., Gasser T.;
RT   "Clinical and molecular characterisation of a Parkinson family with a
RT   novel PINK1 mutation.";
RL   J. Neurol. 255:643-648(2008).
RN   [41]
RP   VARIANT PARK6 PRO-347.
RX   PubMed=22956510; DOI=10.1002/mds.25132;
RA   Kilarski L.L., Pearson J.P., Newsway V., Majounie E., Knipe M.D.,
RA   Misbahuddin A., Chinnery P.F., Burn D.J., Clarke C.E., Marion M.H.,
RA   Lewthwaite A.J., Nicholl D.J., Wood N.W., Morrison K.E.,
RA   Williams-Gray C.H., Evans J.R., Sawcer S.J., Barker R.A.,
RA   Wickremaratchi M.M., Ben-Shlomo Y., Williams N.M., Morris H.R.;
RT   "Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7
RT   (DJ-1) and LRRK2 in early-onset Parkinson's disease.";
RL   Mov. Disord. 27:1522-1529(2012).
CC   -!- FUNCTION: Protects against mitochondrial dysfunction during
CC       cellular stress by phosphorylating mitochondrial proteins.
CC       Involved in the clearance of damaged mitochondria via selective
CC       autophagy (mitophagy) by mediating activation and translocation of
CC       PARK2. Targets PARK2 to dysfunctional depolarized mitochondria
CC       through the phosphorylation of MFN2. Activates PARK2 in 2 steps:
CC       (1) by mediating phosphorylation at 'Ser-65' of PARK2 and (2)
CC       mediating phosphorylation of ubiquitin, converting PARK2 to its
CC       fully-active form (PubMed:24660806, PubMed:24751536,
CC       PubMed:24784582, PubMed:25527291). {ECO:0000269|PubMed:14607334,
CC       ECO:0000269|PubMed:15087508, ECO:0000269|PubMed:19229105,
CC       ECO:0000269|PubMed:19966284, ECO:0000269|PubMed:20404107,
CC       ECO:0000269|PubMed:20798600, ECO:0000269|PubMed:23620051,
CC       ECO:0000269|PubMed:23754282, ECO:0000269|PubMed:23933751,
CC       ECO:0000269|PubMed:24660806, ECO:0000269|PubMed:24751536,
CC       ECO:0000269|PubMed:24784582, ECO:0000269|PubMed:24896179,
CC       ECO:0000269|PubMed:25527291}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:24660806, ECO:0000269|PubMed:24751536,
CC       ECO:0000269|PubMed:24784582}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- SUBUNIT: Interacts with PARK2. Interacts with FBXO7. Forms a
CC       complex with PARK2 and PARK7 (PubMed:19229105).
CC       {ECO:0000269|PubMed:19229105, ECO:0000269|PubMed:19966284,
CC       ECO:0000269|PubMed:20798600, ECO:0000269|PubMed:23933751}.
CC   -!- INTERACTION:
CC       O75530:EED; NbExp=6; IntAct=EBI-2846068, EBI-923794;
CC       Q9Y3I1:FBXO7; NbExp=8; IntAct=EBI-2846068, EBI-1161222;
CC       Q9Y3I1-1:FBXO7; NbExp=2; IntAct=EBI-2846068, EBI-9102965;
CC       Q9GZQ8:MAP1LC3B; NbExp=3; IntAct=EBI-2846068, EBI-373144;
CC       O60260:PARK2; NbExp=7; IntAct=EBI-2846068, EBI-716346;
CC       Q8IXI2:RHOT1; NbExp=3; IntAct=EBI-2846068, EBI-1396430;
CC       Q8WXH5:SOCS4; NbExp=3; IntAct=EBI-2846068, EBI-3942425;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion outer membrane; Single-pass
CC       membrane protein {ECO:0000269|PubMed:15087508,
CC       ECO:0000269|PubMed:18687899, ECO:0000269|PubMed:19229105,
CC       ECO:0000269|PubMed:20798600, ECO:0000269|PubMed:23933751}.
CC       Cytoplasm, cytosol {ECO:0000269|PubMed:19229105,
CC       ECO:0000269|PubMed:20798600}. Note=Localizes mostly in
CC       mitochondrion and the 2 proteolytic processed fragments of 55 kDa
CC       and 48 kDa localize mainly in cytosol.
CC       {ECO:0000269|PubMed:19229105}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1 {ECO:0000269|PubMed:14607334};
CC         IsoId=Q9BXM7-1; Sequence=Displayed;
CC       Name=2 {ECO:0000305};
CC         IsoId=Q9BXM7-2; Sequence=VSP_050754, VSP_050755;
CC         Note=No experimental confirmation available. {ECO:0000305};
CC   -!- TISSUE SPECIFICITY: Highly expressed in heart, skeletal muscle and
CC       testis, and at lower levels in brain, placenta, liver, kidney,
CC       pancreas, prostate, ovary and small intestine. Present in the
CC       embryonic testis from an early stage of development.
CC       {ECO:0000269|PubMed:11494141}.
CC   -!- PTM: Autophosphorylation at Ser-228 and Ser-402 is essential for
CC       Parkin/PARK2 recruitment to depolarized mitochondria.
CC       {ECO:0000269|PubMed:22910362}.
CC   -!- PTM: Two shorter forms of 55 kDa and 48 kDa seem to be produced by
CC       proteolytic cleavage and localize mainly in cytosol.
CC       {ECO:0000269|PubMed:19229105}.
CC   -!- DISEASE: Parkinson disease 6 (PARK6) [MIM:605909]: A
CC       neurodegenerative disorder characterized by parkinsonian signs
CC       such as rigidity, resting tremor and bradykinesia. A subset of
CC       patients manifest additional symptoms including hyperreflexia,
CC       autonomic instability, dementia and psychiatric disturbances.
CC       Symptoms show diurnal fluctuation and can improve after sleep.
CC       {ECO:0000269|PubMed:15087508, ECO:0000269|PubMed:15349860,
CC       ECO:0000269|PubMed:15349870, ECO:0000269|PubMed:15505171,
CC       ECO:0000269|PubMed:15596610, ECO:0000269|PubMed:15955953,
CC       ECO:0000269|PubMed:15970950, ECO:0000269|PubMed:16009891,
CC       ECO:0000269|PubMed:16207217, ECO:0000269|PubMed:16257123,
CC       ECO:0000269|PubMed:16401616, ECO:0000269|PubMed:16482571,
CC       ECO:0000269|PubMed:16632486, ECO:0000269|PubMed:16966503,
CC       ECO:0000269|PubMed:17030667, ECO:0000269|PubMed:18286320,
CC       ECO:0000269|PubMed:22956510}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB053323; BAB55647.1; -; mRNA.
DR   EMBL; AF316873; AAK28062.1; -; mRNA.
DR   EMBL; AK075225; BAC11484.1; -; mRNA.
DR   EMBL; AL391357; CAH73475.1; -; Genomic_DNA.
DR   EMBL; BC009534; AAH09534.1; -; mRNA.
DR   EMBL; BC028215; AAH28215.1; -; mRNA.
DR   CCDS; CCDS211.1; -. [Q9BXM7-1]
DR   RefSeq; NP_115785.1; NM_032409.2. [Q9BXM7-1]
DR   UniGene; Hs.389171; -.
DR   ProteinModelPortal; Q9BXM7; -.
DR   SMR; Q9BXM7; 246-545.
DR   BioGrid; 122376; 61.
DR   DIP; DIP-29427N; -.
DR   IntAct; Q9BXM7; 15.
DR   MINT; MINT-6781189; -.
DR   STRING; 9606.ENSP00000364204; -.
DR   ChEMBL; CHEMBL3337330; -.
DR   iPTMnet; Q9BXM7; -.
DR   PhosphoSite; Q9BXM7; -.
DR   BioMuta; PINK1; -.
DR   DMDM; 48428484; -.
DR   EPD; Q9BXM7; -.
DR   PaxDb; Q9BXM7; -.
DR   PeptideAtlas; Q9BXM7; -.
DR   PRIDE; Q9BXM7; -.
DR   DNASU; 65018; -.
DR   Ensembl; ENST00000321556; ENSP00000364204; ENSG00000158828. [Q9BXM7-1]
DR   GeneID; 65018; -.
DR   KEGG; hsa:65018; -.
DR   UCSC; uc001bdm.3; human. [Q9BXM7-1]
DR   CTD; 65018; -.
DR   GeneCards; PINK1; -.
DR   GeneReviews; PINK1; -.
DR   HGNC; HGNC:14581; PINK1.
DR   HPA; CAB026191; -.
DR   HPA; HPA001931; -.
DR   MalaCards; PINK1; -.
DR   MIM; 168600; phenotype.
DR   MIM; 605909; phenotype.
DR   MIM; 608309; gene.
DR   neXtProt; NX_Q9BXM7; -.
DR   Orphanet; 2828; Young adult-onset Parkinsonism.
DR   PharmGKB; PA33325; -.
DR   eggNOG; KOG4158; Eukaryota.
DR   eggNOG; ENOG410YE6P; LUCA.
DR   GeneTree; ENSGT00390000001206; -.
DR   HOGENOM; HOG000231649; -.
DR   HOVERGEN; HBG053601; -.
DR   InParanoid; Q9BXM7; -.
DR   KO; K05688; -.
DR   OMA; GPKQLAP; -.
DR   OrthoDB; EOG7TBC1R; -.
DR   PhylomeDB; Q9BXM7; -.
DR   TreeFam; TF313183; -.
DR   Reactome; R-HSA-5205685; Pink/Parkin Mediated Mitophagy.
DR   SignaLink; Q9BXM7; -.
DR   SIGNOR; Q9BXM7; -.
DR   ChiTaRS; PINK1; human.
DR   GeneWiki; PINK1; -.
DR   GenomeRNAi; 65018; -.
DR   PRO; PR:Q9BXM7; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; Q9BXM7; -.
DR   CleanEx; HS_PINK1; -.
DR   Genevisible; Q9BXM7; HS.
DR   GO; GO:0097449; C:astrocyte projection; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0030424; C:axon; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0044297; C:cell body; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0000785; C:chromatin; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005856; C:cytoskeleton; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0031307; C:integral component of mitochondrial outer membrane; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0097413; C:Lewy body; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0016020; C:membrane; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005758; C:mitochondrial intermembrane space; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0055131; F:C3HC4-type RING finger domain binding; IPI:BHF-UCL.
DR   GO; GO:0010857; F:calcium-dependent protein kinase activity; IDA:BHF-UCL.
DR   GO; GO:0016301; F:kinase activity; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0016504; F:peptidase activator activity; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0002020; F:protease binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0004672; F:protein kinase activity; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0043422; F:protein kinase B binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0032148; P:activation of protein kinase B activity; IC:ParkinsonsUK-UCL.
DR   GO; GO:0071456; P:cellular response to hypoxia; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0034599; P:cellular response to oxidative stress; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0097237; P:cellular response to toxic substance; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0072655; P:establishment of protein localization to mitochondrion; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB.
DR   GO; GO:0016236; P:macroautophagy; TAS:Reactome.
DR   GO; GO:0072656; P:maintenance of protein location in mitochondrion; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0007005; P:mitochondrion organization; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0000422; P:mitophagy; IMP:UniProtKB.
DR   GO; GO:0098779; P:mitophagy in response to mitochondrial depolarization; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1902902; P:negative regulation of autophagosome assembly; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; ISS:ParkinsonsUK-UCL.
DR   GO; GO:1903384; P:negative regulation of hydrogen peroxide-induced neuron intrinsic apoptotic signaling pathway; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1903298; P:negative regulation of hypoxia-induced intrinsic apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:1903751; P:negative regulation of intrinsic apoptotic signaling pathway in response to hydrogen peroxide; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0046329; P:negative regulation of JNK cascade; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0016242; P:negative regulation of macroautophagy; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0090258; P:negative regulation of mitochondrial fission; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1903147; P:negative regulation of mitophagy; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1903202; P:negative regulation of oxidative stress-induced cell death; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1903204; P:negative regulation of oxidative stress-induced neuron death; TAS:ParkinsonsUK-UCL.
DR   GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0036289; P:peptidyl-serine autophosphorylation; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0016310; P:phosphorylation; NAS:ParkinsonsUK-UCL.
DR   GO; GO:2001171; P:positive regulation of ATP biosynthetic process; TAS:ParkinsonsUK-UCL.
DR   GO; GO:1903852; P:positive regulation of cristae formation; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0033603; P:positive regulation of dopamine secretion; IEA:Ensembl.
DR   GO; GO:1904544; P:positive regulation of free ubiquitin chain polymerization; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IDA:BHF-UCL.
DR   GO; GO:0016239; P:positive regulation of macroautophagy; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1902958; P:positive regulation of mitochondrial electron transport, NADH to ubiquinone; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0090141; P:positive regulation of mitochondrial fission; IBA:GO_Central.
DR   GO; GO:0010952; P:positive regulation of peptidase activity; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0035307; P:positive regulation of protein dephosphorylation; IEA:Ensembl.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IC:ParkinsonsUK-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:AgBase.
DR   GO; GO:1903955; P:positive regulation of protein targeting to mitochondrion; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; IMP:BHF-UCL.
DR   GO; GO:0051091; P:positive regulation of sequence-specific DNA binding transcription factor activity; IEA:Ensembl.
DR   GO; GO:0032226; P:positive regulation of synaptic transmission, dopaminergic; IEA:Ensembl.
DR   GO; GO:0045727; P:positive regulation of translation; IEA:Ensembl.
DR   GO; GO:0051443; P:positive regulation of ubiquitin-protein transferase activity; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IMP:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; IMP:UniProtKB.
DR   GO; GO:0010310; P:regulation of hydrogen peroxide metabolic process; IEA:Ensembl.
DR   GO; GO:0051881; P:regulation of mitochondrial membrane potential; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0010821; P:regulation of mitochondrion organization; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1903146; P:regulation of mitophagy; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0002082; P:regulation of oxidative phosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0061136; P:regulation of proteasomal protein catabolic process; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0043254; P:regulation of protein complex assembly; IDA:BHF-UCL.
DR   GO; GO:1903214; P:regulation of protein targeting to mitochondrion; IDA:AgBase.
DR   GO; GO:0031396; P:regulation of protein ubiquitination; IDA:BHF-UCL.
DR   GO; GO:2000377; P:regulation of reactive oxygen species metabolic process; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1902803; P:regulation of synaptic vesicle transport; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0022904; P:respiratory electron transport chain; IEA:Ensembl.
DR   GO; GO:0006979; P:response to oxidative stress; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0006950; P:response to stress; IDA:UniProtKB.
DR   GO; GO:0038203; P:TORC2 signaling; IC:ParkinsonsUK-UCL.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; TAS:ParkinsonsUK-UCL.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Autophagy; Complete proteome;
KW   Cytoplasm; Disease mutation; Kinase; Magnesium; Membrane;
KW   Metal-binding; Mitochondrion; Mitochondrion outer membrane;
KW   Neurodegeneration; Nucleotide-binding; Parkinson disease;
KW   Parkinsonism; Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Transit peptide;
KW   Transmembrane; Transmembrane helix.
FT   TRANSIT       1     77       Mitochondrion. {ECO:0000255}.
FT   CHAIN        78    581       Serine/threonine-protein kinase PINK1,
FT                                mitochondrial.
FT                                /FTId=PRO_0000024369.
FT   TOPO_DOM     78     93       Mitochondrial intermembrane.
FT                                {ECO:0000255}.
FT   TRANSMEM     94    110       Helical. {ECO:0000255}.
FT   TOPO_DOM    111    581       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      156    511       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000305}.
FT   NP_BIND     162    170       ATP. {ECO:0000250|UniProtKB:Q02750,
FT                                ECO:0000255|PROSITE-ProRule:PRU00159}.
FT   ACT_SITE    362    362       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     186    186       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     228    228       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:22910362}.
FT   MOD_RES     402    402       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:22910362}.
FT   VAR_SEQ       1    307       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_050754.
FT   VAR_SEQ     308    320       LGHGRTLFLVMKN -> MCGSQRPSPLSTS (in
FT                                isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_050755.
FT   VARIANT      67     67       L -> F (in dbSNP:rs763142730).
FT                                {ECO:0000269|PubMed:18330912}.
FT                                /FTId=VAR_046566.
FT   VARIANT      68     68       R -> P. {ECO:0000269|PubMed:18330912}.
FT                                /FTId=VAR_046567.
FT   VARIANT      92     92       C -> F (in PARK6).
FT                                {ECO:0000269|PubMed:15349860}.
FT                                /FTId=VAR_046568.
FT   VARIANT      98     98       R -> W (in dbSNP:rs575668171).
FT                                {ECO:0000269|PubMed:18330912}.
FT                                /FTId=VAR_046569.
FT   VARIANT     111    111       I -> S. {ECO:0000269|PubMed:18330912}.
FT                                /FTId=VAR_046570.
FT   VARIANT     115    115       Q -> L (in dbSNP:rs148871409).
FT                                {ECO:0000269|PubMed:15970950,
FT                                ECO:0000269|PubMed:16009891}.
FT                                /FTId=VAR_046571.
FT   VARIANT     124    124       A -> V. {ECO:0000269|PubMed:18330912}.
FT                                /FTId=VAR_046572.
FT   VARIANT     125    125       C -> G (in PARK6).
FT                                {ECO:0000269|PubMed:16401616}.
FT                                /FTId=VAR_062773.
FT   VARIANT     126    126       Q -> P (in PARK6; strongly reduces
FT                                interaction with PARK2).
FT                                {ECO:0000269|PubMed:18286320,
FT                                ECO:0000269|PubMed:20798600}.
FT                                /FTId=VAR_064344.
FT   VARIANT     145    145       T -> M (in dbSNP:rs45604240).
FT                                {ECO:0000269|PubMed:18330912}.
FT                                /FTId=VAR_046573.
FT   VARIANT     147    147       R -> H (in PARK6; unknown pathological
FT                                significance; dbSNP:rs138050841).
FT                                {ECO:0000269|PubMed:15505171}.
FT                                /FTId=VAR_046574.
FT   VARIANT     148    148       L -> W (in dbSNP:rs56297806).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041010.
FT   VARIANT     168    168       A -> P (in PARK6; has reduced
FT                                autophosphorylation activity compared to
FT                                wild-type; localizes to the mitochondria
FT                                and immunogold experiments reveal that
FT                                both wild-type and mutant proteins face
FT                                the mitochondrial intermembrane space;
FT                                dbSNP:rs768091663).
FT                                {ECO:0000269|PubMed:15349860,
FT                                ECO:0000269|PubMed:16009891,
FT                                ECO:0000269|PubMed:16207731,
FT                                ECO:0000269|PubMed:24784582}.
FT                                /FTId=VAR_046575.
FT   VARIANT     186    186       K -> N (in dbSNP:rs143204084).
FT                                {ECO:0000269|PubMed:18330912}.
FT                                /FTId=VAR_046576.
FT   VARIANT     196    196       P -> L (in PARK6; dbSNP:rs138302371).
FT                                {ECO:0000269|PubMed:16009891}.
FT                                /FTId=VAR_046577.
FT   VARIANT     196    196       P -> S (in dbSNP:rs35802484).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041011.
FT   VARIANT     209    209       P -> L (in dbSNP:rs34677717).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041012.
FT   VARIANT     215    215       P -> L (in a glioblastoma multiforme
FT                                sample; somatic mutation;
FT                                dbSNP:rs371854396).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041013.
FT   VARIANT     217    217       A -> D (in PARK6; dbSNP:rs74315360).
FT                                {ECO:0000269|PubMed:16966503}.
FT                                /FTId=VAR_046578.
FT   VARIANT     231    231       E -> G. {ECO:0000269|PubMed:15596610}.
FT                                /FTId=VAR_046579.
FT   VARIANT     235    235       N -> I. {ECO:0000269|PubMed:15596610}.
FT                                /FTId=VAR_046580.
FT   VARIANT     240    240       E -> K (in PARK6; dbSNP:rs573931674).
FT                                {ECO:0000269|PubMed:15596610,
FT                                ECO:0000269|PubMed:16401616}.
FT                                /FTId=VAR_046581.
FT   VARIANT     257    257       T -> I (in dbSNP:rs370906995).
FT                                /FTId=VAR_046582.
FT   VARIANT     263    263       R -> G. {ECO:0000269|PubMed:15596610}.
FT                                /FTId=VAR_046583.
FT   VARIANT     268    268       L -> V (in PARK6; dbSNP:rs372280083).
FT                                {ECO:0000269|PubMed:16207217,
FT                                ECO:0000269|PubMed:18330912}.
FT                                /FTId=VAR_046584.
FT   VARIANT     271    271       H -> Q (in PARK6; dbSNP:rs28940284).
FT                                {ECO:0000269|PubMed:15349870}.
FT                                /FTId=VAR_046585.
FT   VARIANT     276    276       R -> Q (in dbSNP:rs548506734).
FT                                {ECO:0000269|PubMed:18330912}.
FT                                /FTId=VAR_046586.
FT   VARIANT     279    279       R -> H (in PARK6; dbSNP:rs74315358).
FT                                {ECO:0000269|PubMed:15970950}.
FT                                /FTId=VAR_046587.
FT   VARIANT     280    280       A -> T (in PARK6; early-onset;
FT                                dbSNP:rs772510148).
FT                                {ECO:0000269|PubMed:16482571}.
FT                                /FTId=VAR_062774.
FT   VARIANT     296    296       P -> L (in dbSNP:rs779060308).
FT                                {ECO:0000269|PubMed:15349860,
FT                                ECO:0000269|PubMed:18330912}.
FT                                /FTId=VAR_046588.
FT   VARIANT     305    305       P -> L (in dbSNP:rs7349186).
FT                                /FTId=VAR_018993.
FT   VARIANT     309    309       G -> D (in PARK6; fails to maintain
FT                                mitochondrial membrane potential; has
FT                                reduced autophosphorylation activity
FT                                compared to wild-type; strongly reduces
FT                                interaction with PARK2; decreases PARK2
FT                                and SNCAIP ubiquitination and
FT                                degradation; dbSNP:rs74315355).
FT                                {ECO:0000269|PubMed:15087508,
FT                                ECO:0000269|PubMed:16207731,
FT                                ECO:0000269|PubMed:19229105,
FT                                ECO:0000269|PubMed:20798600}.
FT                                /FTId=VAR_018994.
FT   VARIANT     313    313       T -> M (in PARK6; decreases PARK2 and
FT                                SNCAIP ubiquitination and degradation;
FT                                dbSNP:rs74315359).
FT                                {ECO:0000269|PubMed:17030667,
FT                                ECO:0000269|PubMed:19229105}.
FT                                /FTId=VAR_046589.
FT   VARIANT     317    317       V -> I (in dbSNP:rs200949139).
FT                                {ECO:0000269|PubMed:16969854,
FT                                ECO:0000269|PubMed:18330912}.
FT                                /FTId=VAR_046590.
FT   VARIANT     318    318       M -> L (in dbSNP:rs139226733).
FT                                {ECO:0000269|PubMed:15596610}.
FT                                /FTId=VAR_046591.
FT   VARIANT     322    322       P -> L (in dbSNP:rs768019187).
FT                                {ECO:0000269|PubMed:18330912}.
FT                                /FTId=VAR_046592.
FT   VARIANT     339    339       A -> T (in dbSNP:rs55831733).
FT                                {ECO:0000269|PubMed:15596610,
FT                                ECO:0000269|PubMed:16969854,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:18330912}.
FT                                /FTId=VAR_041014.
FT   VARIANT     340    340       A -> T (in dbSNP:rs3738136).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15349860,
FT                                ECO:0000269|PubMed:15596610,
FT                                ECO:0000269|PubMed:16009891,
FT                                ECO:0000269|PubMed:16257123,
FT                                ECO:0000269|PubMed:16482571,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_018995.
FT   VARIANT     341    341       M -> I (in dbSNP:rs35813094).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041015.
FT   VARIANT     347    347       L -> P (in PARK6; strongly reduces
FT                                interaction with PARK2;
FT                                dbSNP:rs28940285).
FT                                {ECO:0000269|PubMed:15349870,
FT                                ECO:0000269|PubMed:15596610,
FT                                ECO:0000269|PubMed:20798600,
FT                                ECO:0000269|PubMed:22956510}.
FT                                /FTId=VAR_046593.
FT   VARIANT     362    362       D -> H. {ECO:0000269|PubMed:15596610}.
FT                                /FTId=VAR_046594.
FT   VARIANT     369    369       L -> P (in PARK6).
FT                                {ECO:0000269|PubMed:16401616}.
FT                                /FTId=VAR_062775.
FT   VARIANT     377    377       C -> F (in dbSNP:rs34203620).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041016.
FT   VARIANT     383    383       A -> T (in dbSNP:rs45515602).
FT                                {ECO:0000269|PubMed:16969854,
FT                                ECO:0000269|PubMed:18330912}.
FT                                /FTId=VAR_046595.
FT   VARIANT     386    386       G -> A (in PARK6; abolishes kinase
FT                                activity). {ECO:0000269|PubMed:16401616,
FT                                ECO:0000269|PubMed:24784582}.
FT                                /FTId=VAR_062776.
FT   VARIANT     388    388       C -> R (in PARK6).
FT                                {ECO:0000269|PubMed:15955953}.
FT                                /FTId=VAR_046596.
FT   VARIANT     395    395       G -> V. {ECO:0000269|PubMed:18330912}.
FT                                /FTId=VAR_046597.
FT   VARIANT     399    399       P -> L (probable disease-associated
FT                                mutation found in early-onset Parkinson
FT                                disease with digenic inheritance;
FT                                associated with Ser-39 mutation in PARK7
FT                                gene; decreases PARK2 and SNCAIP
FT                                ubiquitination and degradation;
FT                                dbSNP:rs119451946).
FT                                {ECO:0000269|PubMed:16632486,
FT                                ECO:0000269|PubMed:19229105}.
FT                                /FTId=VAR_062777.
FT   VARIANT     407    407       R -> Q (in PARK6; early-onset;
FT                                dbSNP:rs556540177).
FT                                {ECO:0000269|PubMed:16257123}.
FT                                /FTId=VAR_062778.
FT   VARIANT     409    409       G -> V (in PARK6).
FT                                {ECO:0000269|PubMed:16401616}.
FT                                /FTId=VAR_062779.
FT   VARIANT     411    411       G -> S (in dbSNP:rs45478900).
FT                                {ECO:0000269|PubMed:16969854}.
FT                                /FTId=VAR_046598.
FT   VARIANT     417    417       E -> G (in PARK6).
FT                                {ECO:0000269|PubMed:15349870}.
FT                                /FTId=VAR_046599.
FT   VARIANT     425    425       P -> S (in dbSNP:rs554114655).
FT                                {ECO:0000269|PubMed:15596610}.
FT                                /FTId=VAR_046600.
FT   VARIANT     431    431       Y -> H (may predispose to Parkinson
FT                                disease development; shows decreased
FT                                mitochondrial membrane potential under
FT                                stress conditions; dbSNP:rs74315361).
FT                                {ECO:0000269|PubMed:16969854}.
FT                                /FTId=VAR_046601.
FT   VARIANT     442    442       I -> T. {ECO:0000269|PubMed:15349860,
FT                                ECO:0000269|PubMed:18330912}.
FT                                /FTId=VAR_046602.
FT   VARIANT     451    451       N -> S (may predispose to Parkinson
FT                                disease development; shows decreased
FT                                mitochondrial membrane potential under
FT                                stress conditions; dbSNP:rs747400197).
FT                                {ECO:0000269|PubMed:16969854}.
FT                                /FTId=VAR_046603.
FT   VARIANT     461    461       L -> S. {ECO:0000269|PubMed:16969854}.
FT                                /FTId=VAR_046604.
FT   VARIANT     464    464       R -> H (in PARK6; dbSNP:rs764328076).
FT                                {ECO:0000269|PubMed:15349860}.
FT                                /FTId=VAR_046605.
FT   VARIANT     476    476       E -> K (may predispose to Parkinson
FT                                disease development; shows decreased
FT                                mitochondrial membrane potential under
FT                                stress conditions; dbSNP:rs115477764).
FT                                {ECO:0000269|PubMed:15349860,
FT                                ECO:0000269|PubMed:15596610,
FT                                ECO:0000269|PubMed:16009891,
FT                                ECO:0000269|PubMed:16969854,
FT                                ECO:0000269|PubMed:18330912}.
FT                                /FTId=VAR_046606.
FT   VARIANT     477    477       S -> T (in dbSNP:rs34416410).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041017.
FT   VARIANT     489    489       L -> P (in PARK6).
FT                                {ECO:0000269|PubMed:15596610}.
FT                                /FTId=VAR_046607.
FT   VARIANT     501    501       R -> P (may predispose to Parkinson
FT                                disease development; shows decreased
FT                                mitochondrial membrane potential under
FT                                stress conditions).
FT                                {ECO:0000269|PubMed:16969854}.
FT                                /FTId=VAR_046608.
FT   VARIANT     521    521       N -> T (in dbSNP:rs1043424).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15349860,
FT                                ECO:0000269|PubMed:15596610,
FT                                ECO:0000269|PubMed:16009891,
FT                                ECO:0000269|PubMed:16257123,
FT                                ECO:0000269|PubMed:16482571,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_018996.
FT   VARIANT     525    525       D -> N (in dbSNP:rs531477772).
FT                                {ECO:0000269|PubMed:15349860,
FT                                ECO:0000269|PubMed:18330912}.
FT                                /FTId=VAR_046609.
FT   VARIANT     534    534       Q -> QQ (in PARK6).
FT                                {ECO:0000269|PubMed:15970950}.
FT                                /FTId=VAR_046610.
FT   VARIANT     537    537       A -> T (in dbSNP:rs771032673).
FT                                {ECO:0000269|PubMed:18330912}.
FT                                /FTId=VAR_046611.
FT   VARIANT     575    575       C -> R (may predispose to Parkinson
FT                                disease development; shows decreased
FT                                mitochondrial membrane potential under
FT                                stress conditions).
FT                                {ECO:0000269|PubMed:16969854}.
FT                                /FTId=VAR_046612.
FT   MUTAGEN     219    219       K->A: Abolishes MFN2 phosphorylation and
FT                                interaction with PARK2; when associated
FT                                with ALA-362 and ALA-384.
FT                                {ECO:0000269|PubMed:23620051}.
FT   MUTAGEN     362    362       D->A: Abolishes MFN2 phosphorylation and
FT                                interaction with PARK2; when associated
FT                                with ALA-219 and ALA-384.
FT                                {ECO:0000269|PubMed:23620051}.
FT   MUTAGEN     384    384       D->A: Abolishes MFN2 phosphorylation and
FT                                interaction with PARK2; when associated
FT                                with ALA-219 and ALA-362.
FT                                {ECO:0000269|PubMed:23620051}.
FT   CONFLICT    209    209       P -> A (in Ref. 5; AAH28215).
FT                                {ECO:0000305}.
FT   CONFLICT    419    419       S -> P (in Ref. 3; BAC11484).
FT                                {ECO:0000305}.
SQ   SEQUENCE   581 AA;  62769 MW;  721FE01F63263A64 CRC64;
     MAVRQALGRG LQLGRALLLR FTGKPGRAYG LGRPGPAAGC VRGERPGWAA GPGAEPRRVG
     LGLPNRLRFF RQSVAGLAAR LQRQFVVRAW GCAGPCGRAV FLAFGLGLGL IEEKQAESRR
     AVSACQEIQA IFTQKSKPGP DPLDTRRLQG FRLEEYLIGQ SIGKGCSAAV YEATMPTLPQ
     NLEVTKSTGL LPGRGPGTSA PGEGQERAPG APAFPLAIKM MWNISAGSSS EAILNTMSQE
     LVPASRVALA GEYGAVTYRK SKRGPKQLAP HPNIIRVLRA FTSSVPLLPG ALVDYPDVLP
     SRLHPEGLGH GRTLFLVMKN YPCTLRQYLC VNTPSPRLAA MMLLQLLEGV DHLVQQGIAH
     RDLKSDNILV ELDPDGCPWL VIADFGCCLA DESIGLQLPF SSWYVDRGGN GCLMAPEVST
     ARPGPRAVID YSKADAWAVG AIAYEIFGLV NPFYGQGKAH LESRSYQEAQ LPALPESVPP
     DVRQLVRALL QREASKRPSA RVAANVLHLS LWGEHILALK NLKLDKMVGW LLQQSAATLL
     ANRLTEKCCV ETKMKMLFLA NLECETLCQA ALLLCSWRAA L
//
